| What is RSS feed? | About Us |
Show All Time Results | Sort by: Date |  |
 Search Score: 5/10
Source: www.moreover.com --- 7 days ago
- Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. ... Source: www.moreover.com --- 11 days ago
Therapeutics Daily Jul 14 2008 3:52PM GMT ... Source: www.topix.com --- 7 days ago
BioCon Limited and Abraxis BioScience, Inc. Launch ABRAXANE in India for Treatment of Breast Cancer 7/18/2008 BANGALORE, India, & LOS ANGELES-- --Biocon Limited, India's pioneering biotechnology company, and ... ... Source: www.moreover.com --- 9 days ago
Abraxis BioScience, Inc. ... Source: www.moreover.com --- 6 days ago
Bangalore: Biocon Limited and Abraxis BioScience on Friday announced the launch of Abraxane, a medicine for treatment of breast cancer, in India. ... Source: www.moreover.com --- 7 days ago
Bangalore, Jul 18 (UNI) Biocon Technologies, the country's leading biotech company, today launched 'Abraxane,' a solvent free paclitaxel, a first of its kind nano technology drug for metastatic breast cancer, developed by Abraxis BioScience, the ... Source: www.moreover.com --- 7 days ago
Biotechnology major Biocon Ltd will market Abraxane drug of the US-based Abraxis BioScience in India for treating breast cancer, a top company official said here Friday.To be priced at about $400 (Rs. ... Source: www.moreover.com --- 53 days ago
CHICAGO-- (BUSINESS WIRE) -- Abraxis BioScience, Inc. ... Source: www.moreover.com --- 41 days ago
A unit of drug maker Elanwon $55.2m in damages when a federal jury decided rival, Abraxis BioScience Inc, infringed a US patent for medicine used to fight breast cancer. The jury deliberated for 12 hours after an eight-day trial in Delaware. ... Source: www.medicalnewstoday.com --- 51 days ago
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) in combination with bevacizumab for the first-line treatment of metastatic breast cancer. ... Source: seekingalpha.com --- 9 days ago
ChinaBio Today submits: Abraxis BioScience, Inc. (ABII) received SFDA approval for ABRAXANE Paclitaxel for Injection (Albumin Bound) as a breast cancer treatment. The indication was limited to use following failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The approval was based on trials conducted in the US and in China. Currently, Abraxis is conducting trials of ABRAXANE as a first-line chemotherapy for metastatic breast cancer. ABRAXANE is a protein-bound chemotherapy, combining paclitaxel and albumin to deliver the drug. Because the delivery mechanism does not require solvents, a 49% higher dose of the active ingredient, paclitaxel (Taxol), can be given without causing safety issues. In the China Phase III trial, ABRAXANE almost doubled the overall tumor response rate compared to solvent-based paclitaxel (54% vs. 29%), prolonged time to tumor progression by 26% and improved overall survival. These results were more positive than the data from the US trials. Complete Story » ... Source: www.fiercepharma.com --- 18 days ago
A German company is snapping up APP Pharmaceuticals in a deal worth more than $4.6 billion. Fresenius, an $18 billion company that sells products and services to hospitals and home healthcare groups, says the buyout will expand its presence in the lucrative U.S. market. APP, you'll recall, has been in the news this year as the sole remaining U.S. producer of the blood thinner heparin. When Baxter saw its heparin production contaminated, it stopped making most of its heparin products; APP didn't have the same contamination problems, so it ramped up to try to fill the supply gap. APP also makes other injectables such as vitamin supplements, hormones, and diruretics. An interesting side note: APP's recently-ex CEO Patrick Soon-Shiong owns some 83 percent of its stock, so you can bet he's saying ka-ching! Also CEO and a major investor in Abraxis BioScience , Soon-Shiong's share of the APP buyout could amount to as much as $3.8 billion if certain performance targets are met. - read the Wall Street Journal story - see the article in the Los Angeles Times Related Articles: Heparin prices double since recalls Heparin recall spreads in Europe ... Source: www.fiercebiotech.com --- 39 days ago
Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent. Abraxane was approved by the FDA three years ago. This fight is far from finished, as Abraxis says it plans to appeal the ruling. - read the report from RTT News ALSO: Investors are anxiously awaiting a Phase II update from Elan and Wyeth on bapineuzumab , a potential blockbuster drug targeted at the root causes of Alzheimer's. Significant success in the clinic would pave the way for a new drug to compete against therapies that offer little long-term benefit. Report Related Articles: AstraZeneca, Abraxis ink $200M licensing pact Abraxis cleaves company into two new outfits ... Source: www.topix.com --- 51 days ago
Investor and Media Inquiries Daniel Saks, 310-405-7417 DSaks@abraxisbio.com or AstraZeneca Media Inquiries Only Donna Huang, 302-885-6396 donna.huang@astrazeneca.com Abraxis BioScience, Inc. ... Source: www.topix.com --- 3 days ago
July 21, 2008 -- Biotechnology companies , Biocon Limited and Abraxis BioScience, Inc. ... Source: www.cancercompass.com --- 26 days ago
CHICAGO -- Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) in combination with bevacizumab for the first-line treatment of metastatic breast cancer. The preliminary analysis showed that ABRAXANE (ABI-007 or nab-paclitaxel) (125 mg/m2) given weekly for three weeks combined with bevacizumab (10 mg/kg) given weekly on the first and third week of a four-week treatment cycle demonstrated a 33 percent overall response rate and a median progression-free surv... ... Source: medicalusers.com --- 52 days ago
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injecta… medications physical health royalty shoulder body health pet health hand self injury womens health sars leg hospital young mens health [...] ... Find more results for Abraxis BioScience on RSSMicro.com |
|
Copyright © 2008 RSSMicro.com
